DOI:

Inventory reference

ISSN 1812-7231 Klin.inform.telemed. Volume 16, Issue 17, 2021, Pages 00-00

Author(s)

V. N. Sokolov, G.M.Rozhkovska

Institution(s)

Odessa National Medical University, Ukraine

Article title

Oncohematology: a newreality. Lymphoma during the COVID-19 pandemic

Abstract (resume)

The high morbidity and mortality rates reported in patients with hematologic malignancies underscore the vulnerability of this patient population. The risk of delaying potentially curative therapy must be weighed against the risk of an adverse outcome from SARS-CoV-2 should the patient become infected during treatment. There are also data suggesting that patients with lymphoma have an increased susceptibility to infection with SARS-CoV-2. PET-CT (positron emission tomography) is the world's "gold standard" for diagnosing and evaluating the effectiveness of lymphoma treatment. PET allows you to estimate the prevalence of the tumor; if it is not available, the CT with contrast can also help to stage the disease. For patients with a positive interim PET/CT, experts are conservative about escalation of therapy during the COVID-19 pandemic

Keywords

COVID-19, Lymphoma, PET-CT

References

1. V.N. Sokolov, L.V. Anischenko, A.S. Bianov, O.V. Nikitina. [Outside hospital pneumonia. Differential diagnosis of COVID-19]. Klinichna informatika i telemeditsina [J. Klin. inform. and telemed.], 2020, vol. 15, iss. 16, pp.15-28. (in RUS).
https://doi.org/10.31071/kit2020.16.07

2. Poddubnaya I.V., Baryakh E.A., Vorobiev V.I., and others. [Therapy of the Limphoma Hodgkin in Russia during the Pandemic period COVID-19. Resolution.] Sovremennaya onkologiya [Modern oncology], 2020, vol. 22, no. 2, pp. 52-55. (in RUS).

3. Kushchevoy E. V., Filonenko E. S., Titorenko I. B., Cadnikova T. V., Aleksik E. M., Skriphelets T.V., Pastushenko Ya. V. [Digest VII conference with international participation "Modern approaches to diagnosis and treatment of lymphoma"], Klinichna onkolohiya [Clinical Oncology], vol. 10, no. 3-4, pp. 39-40. (in RUS).

4. Liang W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology, 2020; vol. 21, no. 3, pp. 335–7.
https://doi.org/10.1016/S1470-2045(20)30096-6

5. Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA, 2020, vol. 32 no. 3 (18), pp. 1775–1776.
https://doi.org/10.1001/jama.2020.4683

6. Lambertini M., Toss A., Passaro A. et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open, 2020, no.5, e000759.
https://doi.org/10.1136/esmoopen-2020-000759

7. Hanna T.P., Evans G.A., Booth C.M. et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol, 2020, vol. 17, pp. 268–270.

8. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. J. Immunotherapy, 2020, 0(0): imt-2020-0067.
https://doi.org/10.2217/imt-2020-0067

Full-text version